Literature DB >> 30014974

Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors.

Huijuan Mao1, Ting Bao2, Xueyong Shen3, Qing Li4, Christina Seluzicki5, Eun-Ok Im6, Jun J Mao7.   

Abstract

PURPOSE: Fatigue is the most common and distressing symptom experienced by cancer survivors. This study sought to determine the prevalence and risk factors for fatigue among breast cancer (BC) survivors receiving aromatase inhibitors (AIs).
MATERIAL AND METHODS: We conducted a cross-sectional survey study among postmenopausal women with stage 0 to III BC receiving adjuvant AI therapy at the outpatient breast oncology clinic of a large university hospital. Participants with a score ≥4 on the 'worst fatigue' item of the Brief Fatigue Inventory were classified as having moderate or severe fatigue. Multivariate logistic regression analyses were performed to evaluate risk factors.
RESULTS: Among 1103 participants, 616 (55.8%) had moderate or severe fatigue. In the multivariate logistic regression model, women younger than 55 years were significantly more likely to report moderate to severe fatigue than women older than 65 years (adjusted odds ratio [AOR] = 1.58, 95% confidence interval [CI] = 1.07-2.35; p = 0.023). Compared to women with high school or less education, women with college or more education were significantly more likely to report moderate to severe fatigue (AOR = 1.40, 95% CI = 1.02-1.91; p = 0.037). Increasing body mass index (BMI) was significantly associated with increased risk of experiencing moderate to severe fatigue (overweight: AOR = 1.37, 95% CI = 1.01-1.84, p = 0.042; obesity: AOR = 2.08, 95% CI = 1.53-2.81, p < 0.001). Fatigue was significantly correlated with pain severity (r = 0.48, p < 0.001) and insomnia (r = 0.62, p < 0.001).
CONCLUSION: Moderate to severe fatigue complaints exceed 50% among AI users. Fatigue is highly related to younger age, higher education level, higher BMI, pain severity and insomnia.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aromatase inhibitor; Breast cancer; Fatigue

Mesh:

Substances:

Year:  2018        PMID: 30014974      PMCID: PMC6148367          DOI: 10.1016/j.ejca.2018.06.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  40 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  Association of coping style, pain, age and depression with fatigue in women with primary breast cancer.

Authors:  Katrin Reuter; Catherine C Classen; Joseph A Roscoe; Gary R Morrow; Jeffrey J Kirshner; Richard Rosenbluth; Patrick J Flynn; Kathleen Shedlock; David Spiegel
Journal:  Psychooncology       Date:  2006-09       Impact factor: 3.894

3.  Cancer Related Fatigue in Breast Cancer Survivors: in Correlation to Demographic Factors.

Authors:  Fatemeh Moghaddam Tabrizi; Saeedeh Alizadeh
Journal:  Maedica (Buchar)       Date:  2017-06

4.  Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale.

Authors:  T Okuyama; T Akechi; A Kugaya; H Okamura; S Imoto; T Nakano; I Mikami; T Hosaka; Y Uchitomi
Journal:  Support Care Cancer       Date:  2000-05       Impact factor: 3.603

Review 5.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.

Authors:  Brent E Wisse
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

Review 6.  Impact of fatigue on quality of life in oncology patients.

Authors:  G A Curt
Journal:  Semin Hematol       Date:  2000-10       Impact factor: 3.851

7.  Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases.

Authors:  R L Daut; C S Cleeland; R C Flanery
Journal:  Pain       Date:  1983-10       Impact factor: 6.961

8.  Symptom burden clusters: a challenge for targeted symptom management. A longitudinal study examining symptom burden clusters in breast cancer.

Authors:  Elisabeth Kenne Sarenmalm; Maria Browall; Fannie Gaston-Johansson
Journal:  J Pain Symptom Manage       Date:  2013-08-03       Impact factor: 3.612

Review 9.  The complex role of estrogens in inflammation.

Authors:  Rainer H Straub
Journal:  Endocr Rev       Date:  2007-07-19       Impact factor: 19.871

10.  Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

Authors:  Joshua Bauml; Lu Chen; Jinbo Chen; Jean Boyer; Michael Kalos; Susan Q Li; Angela DeMichele; Jun J Mao
Journal:  Breast Cancer Res       Date:  2015-06-28       Impact factor: 6.466

View more
  10 in total

1.  Symptom Clusters in Breast Cancer Survivors: A Latent Class Profile Analysis.

Authors:  Lena Lee; Alyson Ross; Kathleen Griffith; Roxanne E Jensen; Gwenyth R Wallen
Journal:  Oncol Nurs Forum       Date:  2020-01-01       Impact factor: 2.172

2.  Prevalence and correlates of cancer-related fatigue in breast cancer survivors.

Authors:  Alejandro Álvarez-Bustos; Cristina G de Pedro; María Romero-Elías; Javier Ramos; Pablo Osorio; Blanca Cantos; Constanza Maximiano; Miriam Méndez; Carmen Fiuza-Luces; Marta Méndez-Otero; Silvia Martín; Héctor Cebolla; Ana Ruiz-Casado
Journal:  Support Care Cancer       Date:  2021-04-28       Impact factor: 3.603

3.  Prevalence of Sleep Disturbance in Patients With Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mohammed Al Maqbali; Mohammed Al Sinani; Ahmad Alsayed; Alexander M Gleason
Journal:  Clin Nurs Res       Date:  2022-04-28       Impact factor: 1.724

4.  Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.

Authors:  Antonio Di Meglio; Julie Havas; Davide Soldato; Daniele Presti; Elise Martin; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Cecile Charles; Sibille Everhard; Anne-Laure Martin; Charles Coutant; Carole Tarpin; Laurence Vanlemmens; Christelle Levy; Olivier Rigal; Suzette Delaloge; Nancy U Lin; Patricia A Ganz; Ann H Partridge; Fabrice André; Stefan Michiels; Ines Vaz-Luis
Journal:  J Clin Oncol       Date:  2022-01-21       Impact factor: 44.544

5.  Changes in Cardiac Autonomic Modulation in Women with Breast Cancer Using Aromatase Inhibitors and the Relation with Biochemical Variables.

Authors:  Luana Almeida Gonzaga; Thais Reis Silva de Paulo; Juliana Viezel; Laís Manata Vanzella; Ismael Forte Freitas; Luiz Carlos Marques Vanderlei
Journal:  Arq Bras Cardiol       Date:  2019-02-28       Impact factor: 2.000

6.  Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?

Authors:  Tatiana F G Galvão
Journal:  Arq Bras Cardiol       Date:  2019-06-06       Impact factor: 2.000

7.  Effects of infrared laser moxibustion on cancer-related fatigue in breast cancer survivors: Study protocol for a randomized controlled trial.

Authors:  Huijuan Mao; Jun J Mao; Junchao Chen; Qing Li; Xuefen Chen; Xubo Shen; Ling Zhao; Jianzi Wei; Xueyong Shen
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

8.  The long-term course of fatigue following breast cancer diagnosis.

Authors:  Karin Biering; Morten Frydenberg; Helle Pappot; Niels Henrik Hjollund
Journal:  J Patient Rep Outcomes       Date:  2020-05-18

9.  Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy.

Authors:  Fares Mohammed Saeed Muthanna; Mahmathi Karuppannan; Bassam Abdul Rasool Hassan; Ali Haider Mohammed
Journal:  Osong Public Health Res Perspect       Date:  2021-04-29

Review 10.  Cancer-Related Fatigue: Causes and Current Treatment Options.

Authors:  Melissa S Y Thong; Cornelis J F van Noorden; Karen Steindorf; Volker Arndt
Journal:  Curr Treat Options Oncol       Date:  2020-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.